Fas ligand (FasL), an apoptosis-inducing
cytokine, is constitutively expressed on endothelial cells (EC). Here, we report that the soluble form of FasL (sFasL) is released from EC and inhibits
hypoxia-induced EC apoptosis. For
hypoxia experiments, human EC were exposed to low
oxygen tension in airtight chambers flushed with preanalyzed gas mixtures (1%
oxygen, 5% CO2, 94% N2) at 37 degrees C. Exposure of cultured EC to
hypoxia transiently increased FasL
mRNA and
protein levels. The maximum increase was observed at 3 and 6 hours after exposure to
hypoxia, respectively. Although sFasL
protein was not detected in the supernatant from EC without
hypoxia, sFasL
protein level in the supernatant was transiently increased from 6 hours and disappeared again at 24 hours after the exposure to
hypoxia. Interestingly, the supernatant from
hypoxia-exposed EC inhibited EC apoptosis induced by
hypoxia, which was abolished by a
neutralizing antibody against FasL. In addition, incubation with
KB8301, an inhibitor of
metalloproteinase, suppressed the release of sFasL from EC and enhanced
hypoxia-induced apoptosis in EC. Furthermore, exogenously added recombinant sFasL inhibited
hypoxia-induced apoptosis. These findings indicate that sFasL released from EC may inhibit
hypoxia-induced EC apoptosis. Therefore, the shedding of FasL could be a new therapeutic target in regulating
hypoxia-induced EC injury.